Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 22, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: TAKEDA PHARMACEUTICAL CO LTD (10% Owner)
Reporting Person: Takeda Ventures, Inc. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (1248180.0)		Indirect
Series C Preferred Stock	$		Common Stock (226941.0)		Indirect

Footnotes

F1: These shares of the Issuers preferred stock are expected to convert on a one-for-one basis into the number of shares of the Issuers common stock, par value $0.0001 per share (Common Stock), shown in Column 3 immediately upon the closing of the Issuers initial public offering without payment of additional consideration. These shares of the Issuers preferred stock have no expiration date.

F2: This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc.

F3: Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of the 1,248,180 Series B Preferred Stock held by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

F4: Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of the 226,941 Series C Preferred Stock held by Takeda Ventures, Inc.